Dupixent Lawsuit Dupixent lawsuits are being investigated for patients who developed rare blood cancers such as cutaneous T-cell lymphoma (CTCL) after receiving injections, alleging that Sanofi and Regeneron failed to warn about the potential risks of immune suppression and delayed cancer diagnosis.
Tabletop Fire Pit Lawsuit Individuals who suffered severe burns, or families who lost a loved one in a tabletop fire pit explosion, may be eligible for financial compensation through a fire pit injury lawsuit.
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Experimental Drug Claims To Deliver More of Active Ingredient Than Taxotere, Despite Alopecia Concerns April 1, 2016 Irvin Jackson Add Your Comments Amid increasing concerns about the link between permanent hair loss and Taxotere, researchers are looking at a new version of the cancer drug that may deliver more of the active ingredient. The results of a second phase of clinical trials involving a new medication called “CRLX101”, a nanoparticle-drug conjugate (NDC), will be announced later this month at the American Association for Cancer Research Annual Meeting in New Orleans, on April 16 through 20. One of several presentations claim that the experimental drug would be able to deliver more docetaxel, the active ingredient in Taxotere, than Taxotere itself. Do You Know about… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION The presentation will indicate that CRLX101 has pharmacokinetic advantages over Taxotere, resulting in “higher retention of drug in plasma, slower clearance and controlled slow release of docetaxel from the NDC,” according to a March 16 press release by Cerulean, which is developing the drug. However, the findings come as a growing number of patients are filing lawsuits alleging that side effects of Taxotere caused permanent hair loss, or alopecia. The cases claim that alternative breast cancer treatments may have been considered that do not carry the same risks if adequate warnings had been provided by the drug maker. It is unclear what impact on the permanent alopecia risk this new medication may have. Taxotere (docetaxel) was approved by the FDA in May 1996 for treatment of breast cancer, which is given by injection with other chemotherapy drugs. It is used for treatment of patients with locally advanced or metastatic breast cancer after prior chemotherapy attempts had failed, competing with several other treatment alternatives. Allegations raised in recent Taxotere alopecia lawsuits indicate that AstraZeneca knew or should have known about the risk of permanent baldness following chemotherapy treatments with their drug, yet misleadingly indicated that hair generally grows back. In 2005, a study known as GEICAM 9805 found that 9.2% of patients who took Taxotere experienced long-term hair loss for up to 10 years and five months, and in some cases longer. This study was sponsored by Sanofi-Aventis, yet plaintiffs claim information about the permanent hair loss risk was withheld from consumers and the medical community. Reports of Taxotere hair loss problems were also submitted to the drug maker by medical providers. In 2006, at least one Denver-based oncologist reported that 6.3% of patients he treated with Taxotere suffered permanent hair loss for years after taking the drug. Written by: Irvin Jackson Senior Legal Journalist & Contributing Editor Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends. Tags: Alopecia, Breast Cancer, Cancer, Hair Loss, Taxotere Image Credit: | More Taxotere Lawsuit Stories Taxotere Epiphora Lawsuit Filed Over Excessively Watery Eyes March 24, 2023 Lack of Taxotere Warnings Over Blocked Tear Ducts Justify Lawsuits Moving Forward August 2, 2022 Motion Filed to Dismiss Taxotere Lawsuits Over Excessive Tearing Problems July 7, 2022 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Wayfair Fire Pit Lawsuit Links Flame Jetting Explosion to Defective Design (Posted: today) In March 2026, a jury is scheduled to hear a Wayfair fire pit lawsuit from a woman who suffered burns to nearly half her body. MORE ABOUT: TABLETOP FIRE PIT LAWSUITAmazon Tabletop Fire Pit Lawsuit Alleges ‘Flame-Jetting’ Caused Third Degree Burns (08/29/2025)Tabletop Fire Pit Burn Victims Share Stories of Explosions and Devastating Injuries (08/21/2025)Colsen Fire Pit Lawsuit Involving Severe Burn Injuries Suffered by a Child Set for Trial Next Year (08/14/2025) Dupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (Posted: yesterday) Dupixent lawsuits are now being investigated after studies and FDA reports link Dupixent (dupilumab) to cutaneous T-cell lymphoma (CTCL). MORE ABOUT: DUPIXENT LAWSUITDupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025) Depo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (Posted: 2 days ago) A new study appears to further confirm and quantify the risks of Depo-Provera meningioma side effects, potentially providing further evidence for growing litigation. MORE ABOUT: DEPO-PROVERA LAWSUITPfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)Experts Weigh In On Depo-Provera Brain Tumor Risks, As Lawsuits Continue to Mount (08/20/2025)
Wayfair Fire Pit Lawsuit Links Flame Jetting Explosion to Defective Design (Posted: today) In March 2026, a jury is scheduled to hear a Wayfair fire pit lawsuit from a woman who suffered burns to nearly half her body. MORE ABOUT: TABLETOP FIRE PIT LAWSUITAmazon Tabletop Fire Pit Lawsuit Alleges ‘Flame-Jetting’ Caused Third Degree Burns (08/29/2025)Tabletop Fire Pit Burn Victims Share Stories of Explosions and Devastating Injuries (08/21/2025)Colsen Fire Pit Lawsuit Involving Severe Burn Injuries Suffered by a Child Set for Trial Next Year (08/14/2025)
Dupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (Posted: yesterday) Dupixent lawsuits are now being investigated after studies and FDA reports link Dupixent (dupilumab) to cutaneous T-cell lymphoma (CTCL). MORE ABOUT: DUPIXENT LAWSUITDupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025)
Depo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (Posted: 2 days ago) A new study appears to further confirm and quantify the risks of Depo-Provera meningioma side effects, potentially providing further evidence for growing litigation. MORE ABOUT: DEPO-PROVERA LAWSUITPfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)Experts Weigh In On Depo-Provera Brain Tumor Risks, As Lawsuits Continue to Mount (08/20/2025)